Policy | February 01, 2026
Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The state-of-the-art commercial production plant will be built on a 95-acre site in Saarlouis, acquired at the end of 2024
With its unique combination of AI, population-specific research, and international collaboration, BioMed X’s Barbados project represents a bold new frontier in precision medicine for diabetes and kidney disease
The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio
Siegfried plans to grow its exclusive synthesis business in the US by optimizing controlled substance capacity at the Wilmington and nearby Pennsville sites
Growth across inorganic & organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents
Subscribe To Our Newsletter & Stay Updated
